EP 1147078 A1 20011024 - ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
Title (en)
ACETYLENIC (BETA)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
Title (de)
ACETYLENISCHE (BETA)-SULFONAMIDO UND PHOSPHINSÄUREAMID HYDROXAMSÄURE TACE INHIBITOREN
Title (fr)
INHIBITEURS DES TACE A BASE D'ACIDES HYDROXAMIQUES DES ACIDES PHOSPHINIQUE ET (BETA)-SULFONAMIDO ACETYLENIQUE
Publication
Application
Priority
- US 0001865 W 20000127
- US 23908399 A 19990127
Abstract (en)
[origin: WO0044711A1] The invention discloses hydroxamide acids of formula (B) which are useful in treating disease conditions mediated by TNF- alpha , such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss. In the above formula, the dotted line represents an optional double bond, and R5, R6, R7, R8, R11, R12, X, Y and Z have the meanings given in the specification.
IPC 1-7
IPC 8 full level
A61K 31/18 (2006.01); A61K 31/196 (2006.01); A61K 31/197 (2006.01); A61K 31/215 (2006.01); A61P 1/04 (2006.01); A61P 1/02 (2006.01); A61P 1/06 (2006.01); A61P 1/16 (2006.01); A61P 3/10 (2006.01); A61P 7/02 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); A61P 9/10 (2006.01); A61P 9/14 (2006.01); A61P 13/12 (2006.01); A61P 15/06 (2006.01); A61P 17/00 (2006.01); A61P 19/00 (2006.01); A61P 19/02 (2006.01); A61P 19/04 (2006.01); A61P 25/00 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 31/04 (2006.01); A61P 31/18 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); A61P 37/02 (2006.01); A61P 43/00 (2006.01); C07C 303/40 (2006.01); C07C 309/42 (2006.01); C07C 309/87 (2006.01); C07C 311/29 (2006.01)
CPC (source: EP KR)
A61P 1/02 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 1/06 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 7/02 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/04 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 9/14 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 15/06 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 19/00 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/04 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/18 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 35/04 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07C 309/42 (2013.01 - EP); C07C 309/87 (2013.01 - EP); C07C 311/29 (2013.01 - EP); C07F 9/53 (2013.01 - KR); C07C 2601/08 (2017.05 - EP); C07C 2601/14 (2017.05 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0044711 A1 20000803; AR 035478 A1 20040602; AU 2630600 A 20000818; AU 769410 B2 20040129; BR 0007754 A 20011113; CA 2356345 A1 20000803; CN 1337944 A 20020227; CZ 20012709 A3 20020417; EA 200100808 A1 20011224; EP 1147078 A1 20011024; HU P0200605 A2 20020729; HU P0200605 A3 20050530; IL 144321 A0 20020523; JP 2002535383 A 20021022; KR 20010089617 A 20011006; NO 20013639 D0 20010724; NO 20013639 L 20010724; NZ 512025 A 20030829; ZA 200104508 B 20020902
DOCDB simple family (application)
US 0001865 W 20000127; AR P000100325 A 20000126; AU 2630600 A 20000127; BR 0007754 A 20000127; CA 2356345 A 20000127; CN 00803031 A 20000127; CZ 20012709 A 20000127; EA 200100808 A 20000127; EP 00904570 A 20000127; HU P0200605 A 20000127; IL 14432100 A 20000127; JP 2000595968 A 20000127; KR 20017009153 A 20010720; NO 20013639 A 20010724; NZ 51202500 A 20000127; ZA 200104508 A 20010531